3 Insider Plays With 1,000% Potential

There’s so much information to consider when evaluating a stock. Of course, there are the company’s revenue, profits, cash position, and the like, but there are also a slew of ratios and percentages that can certainly be informative.

At the end of the day, though, one metric stands head and shoulders above the rest when evaluating which direction a stock is headed: insider buying.

Insiders know more about their companies than any investor could ever hope to. They know the direction of sales since the last quarterly report and upcoming product releases. There are also intangibles we could never even guess at, like office morale.

Insiders can’t just forget about everything they know when they invest. So they need to tell us when they buy or sell their company’s shares and in what quantity. And when you see insiders loading up on shares, then it’s a very safe bet they know their company’s stock is about to take off.

After all, an insider might sell shares for any number of reasons, maybe they are buying a house or paying for their kid’s college. But they buy shares for only one reason: They believe those shares are about to go up in value.

Following insiders is, in my humble opinion, the simplest investment strategy out there. And it all boils down to four simple rules that give us a much bigger chance to win.

1. I want to see purchases of over $1,000,000.
2. I want to see a cluster of insiders all buying at once or in rapid succession.
3. I want to see more buying than selling among insiders.
4. And, ideally, I want to see an insider with a great track record buy.

High-level insiders are rapidly shifting out of Big Tech. There were ZERO insider buys in seven of the biggest tech stocks in the world in 2024.

The insider migration is growing faster by the day, and we are tracking where they are going. We don’t listen to the media or what the insiders SAY. We watch what they DO.

Follow the money… Money never lies.

The three companies in this report match my criteria and then some. Each one has 1,000% potential, and their leadership certainly agrees.

A Star Is Born

Based in Covington, Louisiana, Globalstar is an up-and-coming satellite services company in a booming industry, one that’s growing at a compound annual rate of 30% and is set to be worth just shy of $16 billion by 2030.

I would wager the average person doesn’t think too much about how their phone calls or text messages get to the other end of their conversation. But regardless of where you live, there’s a decent chance your words are going to space…

Satellites are the invisible infrastructure the modern economy relies on, especially for remote areas and industries that operate over a large geographical area. And Globalstar’s network covers 13.4 million square miles in 12 countries across four continents and covers about 1 billion people.

For instance, farmers can use satellite imaging to keep track of their herds and crop fields. Oil and gas companies use satellites to communicate with offshore drilling rigs and massive oil tankers out at sea. Logging companies use them to keep track of their lumberjacks and assist in the event of an emergency in a remote area. Not to mention, the emerging Internet of Things (IoT) is reliant on connectivity. And in remote locations, that means it’s reliant on satellites. On top of all that, there are the military applications of satellite imagery and communications…

Globalstar provides all of that and more to its clients.

Let’s look at what the oil and gas industry, the company’s largest revenue source, uses Globalstar’s products for…

One of the biggest roles of the oil and gas industry is finding new sources through the process of exploration. Companies engaged in exploration often send individuals or small teams to remote and often harsh environments where they collect vast reams of data. There’s no cell coverage out there; the infrastructure doesn’t exist.

So Globalstar’s satellite network fixes the problem by providing workers with a reliable line of communication. No infrastructure required. It allows for real-time communications between all sites and control centers in a cost-effective way. The satellite network also provides reliable communication between oil rigs and onshore operations.

Put it all together and you have an end-to-end suite of satellite and communication for any company’s or government’s needs. Globalstar’s network allows for a wide range of uses that can be easily tailored to many applications, disrupting and innovating in an already disruptive industry.

And Globalstar is making a mint doing it…

Let’s start with revenue. For fiscal year 2023, the company brought in revenue of $223.81 million, up 50.71% over fiscal year 2022’s. The company has been on a tear, with revenue growing at a compound annual rate of 25% over the past three years.

Annual earnings per share are a similar story. The company saw 124.76% growth from 2021 to 2022 and 86% growth from 2022 to 2023. On a quarterly basis, the company has the growth I’m looking for, too. For Q3 2024, revenue came in at $72.31 million, up 25.35% over Q3 2023’s revenue.

In addition, the company landed a $1.1 billion deal with Apple to expand its satellite network for iPhones. The deal provided Globalstar with enough capital to retire its outstanding 2029 debt. Its total net debt has been reduced to $371 million.

Now let’s look at insider buying. One director, former CEO James Monroe, made six massive purchases in December 2024. Five of them were for half a million shares. One of them was for 530,000 shares. In total, he bought almost $6 million worth of shares, which brought his total shares up to 11.33 million.

Over the past 12 months, insiders have collectively purchased $13.53 million worth of shares and insiders have sold just $8.71 million worth by comparison. That’s the sort of big cluster buying I love to see, and it’s why I think Globalstar is in for a fantastic 2025…

Action to Take: Buy Globalstar Inc. (Nasdaq: GSAT) at market. Set a 25% trailing stop to protect your principal and your profits.

The Revolution Will Not Be Televised… But It Will Be Profitable

The United States sees nearly 1.8 million new cases of cancer each year. Cancer is unique as far as diseases go. It’s not a virus or bacteria; it’s a person’s cells refusing to die like they’re supposed to and growing out of control.

Normally, the means of treating it do as much damage to the patient as they do to the disease. Chemotherapy and radiation sometimes kill the patient before the cancer does. But Revolution Medicines Inc. (Nasdaq: RVMD) is changing that…

The biotech company has three drugs in its pipeline meant to fight a specific subset of cancers called RAS-addicted cancers. These cancers grow by activating renin-angiotensin system, or RAS, proteins, which control cell growth.

Over 90% of pancreatic cancer cases, 45% of colorectal cancer cases, 25% of lung cancer cases, and some cases of melanoma and thyroid cancers are RAS-addicted.

The drugs in Revolution’s pipeline, Daraxonrasib, Elironrasib, and Zoldonrasib function by inhibiting the activation of RAS proteins. In combination, these drugs have been able to eliminate a tumor within a matter of months without the awful side effects of traditional chemo and radiation therapies.

All three drugs are currently in early clinical development. One of them, Daraxonrasib, is registering for a trial.

In early stages, the drug showed a 100% disease control rate in 17 non-small cell lung cancer patients. It’s effectively a cure for a wide range of cancers, the holy grail of modern medicine. And company insiders seem to believe in the potential of its drugs…

One director, Thilo Schroeder, bought 1.3 million shares in December 2024 for a total of nearly $60 million. That’s a vote of confidence if I’ve ever seen one. And consider that the last time he bought shares was in March of 2023, and shares are up 94% since then. So he’s already sitting on $13 million in profits.

And his December purchase was four times larger than his March 2023 one.

Now, this is a young biotech, so there isn’t much financial data to report. But considering that Revolution may have just cured cancer – at least some types of cancer – and Schroeder just made a $60 million vote of confidence, I don’t think that will remain the case for long.

One breakthrough can send a biotech on a moonshot. In 2024, Summit Therapeutics jumped 1,000%. Eli Lilly went on a 1,241% run. And GeneDx soared 2,762%…

I think Revolution Medicines could very well be on the doorstep of its own revolutionary moonshot…

Action to Take: Buy Revolution Medicines Inc. (Nasdaq: RVMD) at market. Set a 25% trailing stop to protect your principal and your profits.

Insurance Policy

Health insurance is big business. In the United States, the health insurance market is worth $1.78 trillion and is expected to hit $3.63 trillion by 2034. And Oscar Health Inc. (NYSE: OSCR) is an up-and-comer in the space dedicated to making healthcare more affordable and provide the best member experience on the market.

A full 48% of insured adults worry about their ability to pay monthly premiums. Beyond the cost, dealing with your health insurance company can be incredibly painful, particularly if you have a chronic illness.

You have to get on the phone with robots and play phone tag with any human agent you can get in order to afford the drugs or treatments you need to function. It’s miserable for millions of people.

But Oscar maintains an 82% member retention rate by offering an easy-to-use service with sympathetic customer service teams. And it appears to be working well…

The company’s membership has been growing at a 40% CAGR over the past three years. In 2021, the company had 542,000 members, and today it has over 1.5 million.

And the financial data speaks for itself. For its full-year 2024, Oscar took in $8.9 billion in premiums, up 57.8% over 2023’s. Total revenues for 2024 topped $9.1 billion, up 56.6% over 2024’s.

Over the past three years, revenue has grown at a CAGR of 69%. The company holds $1.53 billion in cash and has a gross margin of 20.1%. And right now, it’s trading at bargain-basement prices. Perhaps that’s why insiders have been loading up on shares…

In the last 12 months, insiders have purchased $14.43 million in shares. Most notably, in November of 2024, Joshua Kushner, the vice chairman of the board, bought just shy of $4.9 million worth.

Joshua Kushner is the brother of Jared Kushner, Donald Trump’s son-in-law. Jared has also picked up some shares of Oscar. Joshua has an in both with Oscar and with the new president’s developing healthcare policy. If he loads up on millions of dollars’ worth of shares, I would wager Oscar is in for a very good year, and potentially a very good four years.

I would follow suit, and right now, you can get in for less than $15 per share.

Action to Take: Buy Oscar Health Inc. (NYSE: OSCR) at market. Set a 25% trailing stop to protect your principal and your profits.

Get Your Own Man on the Inside

Insider buying is hands down the best metric to look at when evaluating a stock.

Large numbers of insiders buying shares of their own companies in large quantities is one of the best buy signals on the market.

And all of them are required by law to report their trades. Every corporate insider is our man or woman on the inside.

By following their moves, we will be well on our way to racking up 100%, 500%, and even 1,000% gains. Each of these companies has the potential to do exactly that if you buy in today.